We Can Treat Hodgkin’s Lymphoma Like Melanoma?
Isabel Cunningham, MD, Cancer Therapy Advisor Advisory Board member, weighs in on recent discoveries in the treatment of hematologic cancers.
Isabel Cunningham, MD, Cancer Therapy Advisor Advisory Board member, weighs in on recent discoveries in the treatment of hematologic cancers.
Involved-field radiotherapy (IF-RT) should be considered standard of care for stage 1A nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).
Recent declines in nodular sclerosis (NS) rates represented true incidence changes in Hodgkin lymphoma (HL).
For Hodgkin’s lymphoma, brentuximab vedotin is associated with improved progression-free survival after autologous stem-cell transplant.
PET-adapted sequential salvage therapy with brentuximab could optimize chance of cure in relapsed and refractory Hodgkin lymphoma.
Socioeconomic factors affect selection of curative treatments in Hodgkin lymphoma.
Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) is the standard of care for early-stage favorable Hodgkin’s lymphoma
Brentuximab vedotin in Hodgkin lymphoma at risk for progression following autologous stem cell transplantation (ASCT) resulted in better survival.
Patients with classical Hodgkin lymphoma (cHL) who were heavily pretreated had clinical benefit from pembrolizumab (MK-3475).
Combination therapy with perifosine and sorafenib effective and safe for the treatment of relapsed or refractory Hodgkin lymphoma.